Now live: Pro — the full 13F research suite for serious investorsSee pricing →
BOONE CAPITAL MANAGEMENT LLC

Q4 2023 · 13F-HR

BOONE CAPITAL MANAGEMENT LLCholdings as filed

Filed 2024-02-14 · accession 0001214659-24-002812

$428.4M
Reported value
21
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
91529Y106UNMUNUM GROUP$43.5M10.2%961,661CommonSOLE
194014502ENOVENOVIS CORPORATION$31.5M7.36%562,739CommonSOLE
031162100AMGNAMGEN INC$29.2M6.82%101,508CommonSOLE
126650100CVSCVS HEALTH CORP$29.0M6.77%367,370CommonSOLE
379577208GMEDGLOBUS MED INC$28.2M6.59%529,825CommonSOLE
125523100CITHE CIGNA GROUP$26.8M6.27%89,640CommonSOLE
235851102DHRDANAHER CORPORATION$25.1M5.86%108,501CommonSOLE
03209R103AMPHAMPHASTAR PHARMACEUTICALS IN$24.7M5.77%400,000CommonSOLE
60855R100MOHMOLINA HEALTHCARE INC$24.7M5.76%68,288CommonSOLE
071813109BAXBAXTER INTL INC$21.2M4.95%548,536CommonSOLE
92556V106VTRSVIATRIS INC$20.7M4.83%1,912,272CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$18.9M4.42%531,967CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$17.8M4.15%440,845CommonSOLE
08579W103BERYEURBERRY GLOBAL GROUP INC$15.6M3.64%231,456CommonSOLE
74766Q101QTRXQUANTERIX CORP$15.5M3.63%568,544CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$14.5M3.38%490,139CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$11.8M2.75%255,432CommonSOLE
090572207BIOBIO RAD LABS INC$11.5M2.69%35,713CommonSOLE
68752M108OFIXORTHOFIX MED INC$6.7M1.57%500,000CommonSOLE
59064R109MLABMESA LABS INC$6.7M1.57%64,064CommonSOLE
70805E109PNTGPENNANT GROUP INC$4.6M1.07%329,660CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.